The ‘severe, persistent, and disruptive’ shortages often impact patients with ADHD, menopause and diabetes, a new report says ...

Labels of all extended-release stimulants indicated for ADHD -- including certain formulations of amphetamine and ...

The findings also highlight how shortages severely impact patients with conditions like ADHD, menopause and diabetes.

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Kids younger than 6 years on extended-release stimulants for ADHD may experience higher rates of side effects due to higher plasma exposures.

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Medications for attention-deficit/hyperactivity disorder (ADHD) have some side effects that are common, while others are more ...

Instead, participants said, classifying methylphenidate a schedule 6 drug “ negatively impacts on treatment adherence ”. Our medicines regulator, the South African Health Products Regulatory Authority ...

The agency said it assessed data from clinical trials of extended-release formulations of amphetamine and methylphenidate for ADHD treatment, finding that, compared to older children, patients ...

A new generation of long-acting methylphenidate formulations are now available for the treatment of ADHD. This review analyzes 34 comparative studies to help inform clinical decision-making.

The use of stimulant medications to treat ADHD remains stigmatized to some degree. But these medications aren't only effective; they may even promote brain growth.

Stanford University researchers have discovered why some people with attention deficit hyperactivity disorder may do well on their medicine for a while but struggle down the road.